← Back to Search

Electromagnetic Technology

BTL Emsella for Stress Urinary Incontinence

N/A
Recruiting
Led By Kenneth Peters, MD
Research Sponsored by William Beaumont Hospitals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
For Females Only: Subject agrees to discontinue use of bladder support devices, including but not limited to vaginal pessary, during the screening, treatment, and follow-up periods.
Subject agrees not to start any new treatment (medication or otherwise) during the treatment and follow-up periods.
Must not have
For Females Only: Pregnant, or planning to become pregnant, at screening or anytime throughout the study period
Subject is morbidly obese (defined as body mass index 40 or greater)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks after primary efficacy endpoint

Summary

This trial will test if the Emsella chair, which uses electromagnetic waves to strengthen pelvic muscles, is effective for people with stress urinary incontinence. The goal is to see if this treatment can reduce urine leakage during activities like exercise or laughing. This new technology is used for pelvic muscle strengthening for the treatment of stress urinary incontinence.

Who is the study for?
This trial is for men and women aged 18-80 with stress urinary incontinence, who can consent to the study's requirements. Participants must not start new treatments or change current medication doses during the study. Women using bladder support devices or of childbearing age must follow specific guidelines, while men should be post-prostatectomy.
What is being tested?
The trial tests the Emsella chair against a sham (fake treatment) to see if electromagnetic technology helps treat involuntary urine leakage caused by pressure from activities like coughing or laughing.
What are the potential side effects?
Potential side effects are not explicitly listed but may include discomfort due to sitting on the chair, skin sensation changes where electromagnetic waves pass, and possible muscle contractions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I agree to not use any bladder support devices during the study.
Select...
I agree not to start new treatments during the study period.
Select...
I am between 18 and 80 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not pregnant and do not plan to become pregnant during the study.
Select...
My BMI is 40 or higher.
Select...
I have a piercing between my waist and knees and won't remove it for treatment.
Select...
I am not currently receiving treatment for another cancer that would affect my participation.
Select...
I experience breathing difficulties, chest pain, and other related symptoms.
Select...
I have a confirmed urinary tract infection that needs treatment.
Select...
I cannot feel my pelvis, buttocks, or legs normally.
Select...
I have had surgery to insert vaginal mesh for stress urinary incontinence.
Select...
I have been diagnosed with vesicoureteral reflux.
Select...
I have undergone pelvic floor physical therapy in the last 30 days.
Select...
I have an active urethral diverticulum.
Select...
I have bladder control issues due to a condition like MS, Parkinson's, or spinal injury.
Select...
I have a vaginal prolapse that extends outside the opening.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks after completing all treatments
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks after completing all treatments for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Urinary Stress Incontinence
Secondary study objectives
Durability to determine whether subjects in the Emsella Chair group continue to have a higher responder rate than the Sham group
Safety objective to determine the safety and tolerability of Emsella Chair compared to sham
The efficacy of the Emsella chair versus sham to treat SUI in relation to the change in subject-reported impression of SUI severity.
+9 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Emsella Chair Active TreatmentActive Control1 Intervention
Active treatment subjects will be asked to sit on the center of the Emsella chair. The height of the chair will be adjusted until the participant's feet are on the floor. The Emsella chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will then be decreased slightly and stay unchanged for the remainder of the treatment time. The treatment threshold should be increased with every treatment until the subject reaches 100%.
Group II: Emsella Sham TreatmentPlacebo Group1 Intervention
Sham subjects will be positioned on the device in the same manner as the active treatment group. The sham treatment will be provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (\<10% power).

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Stress Urinary Incontinence (SUI) is commonly treated through pelvic floor muscle training (PFMT), surgical interventions, and more recently, electromagnetic technology like the Emsella chair. PFMT strengthens the pelvic floor muscles, which support the bladder and urethra, reducing urine leakage during activities that increase intra-abdominal pressure. Surgical options, such as sling procedures, provide structural support to the urethra. The Emsella chair uses high-intensity focused electromagnetic (HIFEM) technology to stimulate deep pelvic floor muscles, enhancing their strength and endurance without the need for active patient participation. Understanding these mechanisms is crucial for SUI patients as it helps them make informed decisions about their treatment options, considering factors like invasiveness, required effort, and potential effectiveness.

Find a Location

Who is running the clinical trial?

William Beaumont HospitalsLead Sponsor
151 Previous Clinical Trials
112,500 Total Patients Enrolled
Kenneth Peters, MDPrincipal InvestigatorBeaumont Hospital-Royal Oak
26 Previous Clinical Trials
1,916 Total Patients Enrolled

Media Library

BTL Emsella (Electromagnetic Technology) Clinical Trial Eligibility Overview. Trial Name: NCT04133675 — N/A
Stress Incontinence Research Study Groups: Emsella Chair Active Treatment, Emsella Sham Treatment
Stress Incontinence Clinical Trial 2023: BTL Emsella Highlights & Side Effects. Trial Name: NCT04133675 — N/A
BTL Emsella (Electromagnetic Technology) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04133675 — N/A
~40 spots leftby Oct 2027